Repository logo
 

Plasma Metabolites Related to the Consumption of Different Types of Dairy Products and Their Association with New-Onset Type 2 Diabetes: Analyses in the Fenland and EPIC-Norfolk Studies, United Kingdom.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

SCOPE: To identify metabolites associated with habitual dairy consumption and investigate their associations with type 2 diabetes (T2D) risk. METHODS AND RESULTS: Metabolomics assays were conducted in the Fenland (n = 10,281) and EPIC-Norfolk (n = 1,440) studies. Using 82 metabolites assessed in both studies, we developed metabolite scores to classify self-reported consumption of milk, yogurt, cheese, butter, and total dairy (Fenland Study-discovery set; n = 6035). Internal and external validity of the scores was evaluated (Fenland-validation set, n = 4246; EPIC-Norfolk, n = 1440). The study assessed associations between each metabolite score and T2D incidence in EPIC-Norfolk (n = 641 cases; 16,350 person-years). The scores classified low and high consumers for all dairy types with internal validity, and milk, butter, and total dairy with external validity. The scores were further associated with lower incident T2D: hazard ratios (95% confidence interval) per standard deviation: milk 0.71 (0.65, 0.77); butter 0.62 (0.57, 0.68); total dairy 0.66 (0.60, 0.72). These associations persisted after adjustment for known dairy-fat biomarkers. CONCLUSION: Metabolite scores identified habitual consumers of milk, butter, and total dairy products, and were associated with lower T2D risk. These findings hold promise for identifying objective indicators of the physiological response to dairy consumption.

Description

Journal Title

Mol Nutr Food Res

Conference Name

Journal ISSN

1613-4125
1613-4133

Volume Title

Publisher

Wiley

Rights and licensing

Except where otherwised noted, this item's license is described as All rights reserved
Sponsorship
MRC (5PV0E)
MRC (MC_PC_13046)
Medical Research Council (MR/N003284/1)
MRC (MC_UU_00006/1)
MRC (MC_UU_00006/3)
MRC (MC_UU_00006/4)
MRC (MC_UU_00006/6)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Department of Health (via National Institute for Health Research (NIHR)) (NIHR202397)
National Institute for Health and Care Research (IS-BRC-1215-20014)
Medical Research Council (MC_UU_12015/3)
Cancer Research Uk (None)
Medical Research Council (MC_PC_13046)
The Fenland study (DOI:10.1186/ISRCTN72077169) was funded by the Medical Research Council and the Wellcome Trust. The EPIC-Norfolk study (DOI:10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 and MC_UU_00006/1) and Cancer Research UK (C864/A14136). Metabolite measurements in the EPIC-Norfolk study were supported by the MRC Cambridge Initiative in Metabolic Science (MR/L00002/1) and the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372. The current work was supported by the Medical Research Council (grant numbers MC_UU_00006/3, MC_UU_00006/1, MC_UU_00006/4). NGF, AK, SB and NJW acknowledge support from the NIHR Cambridge Biomedical Research Centre (IS-BRC-1215-20014; NIHR203312) and NGF is an NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. ET received funding from the Cambridge Trust and the Medical Research Council Epidemiology Unit.